| Document Date: 2013-04-02 09:23:50
Open Document File Size: 313,77 KBShare Result on Facebook
Company Flagship Ventures / Polaris Partners / Flybridge Capital Partners / TARIS Biomedical / Third Rock Ventures / / Country United States / Canada / / Currency USD / / Event FDA Phase / Funding / / Facility Massachusetts Institute of Technology / / IndustryTerm venture capital / pharmaceutical / stage specialty pharmaceutical / / MedicalCondition bladder diseases / overactive bladder / disease / Bladder Disease Bladder diseases / Bladder Pain Syndrome / urinary incontinence / complex bladder diseases / bladder cancer / Interstitial Cystitis / pain syndrome / pain / chronic pelvic pain syndromes / diseases / urinary tract infections / / Organization Massachusetts Institute of Technology / / Person Lexington / Robert Langer / Michael Cima / Purnanand Sarma / / Position President and CEO / Candidate / / Product Lidocaine / Lead Product Candidate / LiRIS® / / ProvinceOrState Massachusetts / / URL www.tarisbiomedical.com / /
SocialTag |
TARIS® Secures $12.5 Million in Additional Financing; Initiates Phase 2 Trial of Lead Product Candidate Lexington, MA – April 2nd, 2013 – TARIS Biomedical®, a specialty pharmaceutical company developing innovative,